import Image from "next/image"
import Link from "next/link"

/**
 * Longform editorial for /category/research-blends.
 * Intro, TOC, conclusion. RUO. Cited. Images unchanged.
 */
export function ResearchBlendsContent() {
  return (
    <article className="mx-auto max-w-4xl space-y-12 py-4 text-[#0F172A]">
      <section className="space-y-4">
        <h2 className="font-serif text-2xl text-[#0F172A]">Introduction: what research blends are for</h2>
        <p className="leading-relaxed text-[#475569]">
          Research blends are fixed-ratio peptide reagents. One vial, one lot, a set list of components. Labs
          use them when the study already asks a multi-pathway question and every replicate needs the same
          mix.
        </p>
        <p className="leading-relaxed text-[#475569]">
          They are a poor fit when the protocol has to isolate one receptor or build a dose-response for one
          sequence. A fixed ratio will not let you lower one peptide while holding the other constant.
        </p>
        <p className="leading-relaxed text-[#475569]">
          Most "peptide blends for sale" pages skip that distinction. They treat the longest label as the
          best peptide blend. That is a marketing habit, not a lab rule. A blend is only strong when every
          component has a reason to be there, the ratio matches the assay, and the COA proves what is in the
          vial. Tetrava lists these as{" "}
          <Link href="/" className="text-[#0D9488] hover:underline">
            research peptides
          </Link>
          . Research use only.
        </p>
        <p className="leading-relaxed text-[#475569]">
          Search interest in research blends and peptide blends usually splits into two jobs: finding a
          fixed-ratio reagent for a multi-pathway screen, and shopping for documentation that will survive a
          methods audit. This page is built for both.
        </p>
      </section>

      <nav className="rounded-xl border border-[#E2E8F0] bg-[#F8FAFC] p-6">
        <p className="mb-3 font-medium text-[#0F172A]">Table of contents</p>
        <ol className="list-decimal space-y-2 pl-5 text-sm text-[#475569]">
          <li>
            <a href="#blend-vs-single" className="text-[#0D9488] hover:underline">
              Blend vs. single-compound controls
            </a>
          </li>
          <li>
            <a href="#blend-families" className="text-[#0D9488] hover:underline">
              Four peptide blend families
            </a>
          </li>
          <li>
            <a href="#naming-traps" className="text-[#0D9488] hover:underline">
              Nicknames vs. catalog identity
            </a>
          </li>
          <li>
            <a href="#best-blend" className="text-[#0D9488] hover:underline">
              How to choose the best peptide blend for a study
            </a>
          </li>
          <li>
            <a href="#evidence-problem" className="text-[#0D9488] hover:underline">
              Why blend evidence is harder
            </a>
          </li>
          <li>
            <a href="#storage" className="text-[#0D9488] hover:underline">
              Storage and prep notes for multi-peptide vials
            </a>
          </li>
          <li>
            <a href="#buying-checks" className="text-[#0D9488] hover:underline">
              Checks before buying peptide blends for sale
            </a>
          </li>
        </ol>
      </nav>

      <section id="blend-vs-single" className="space-y-4">
        <h2 className="font-serif text-2xl text-[#0F172A]">Blend vs. single-compound controls</h2>
        <p className="leading-relaxed text-[#475569]">
          A blend locks the ratio. Put BPC-157 and TB-500, or cagrilintide and semaglutide, in one vial and
          every well gets the same relative load. Prep variation drops. Flexibility drops with it. If the
          assay needs less semaglutide than amylin analogue, stop using the blend.
        </p>
        <p className="leading-relaxed text-[#475569]">
          A blend also collapses lot tracking. Three separate peptides mean three lot IDs, three COAs, three
          handling logs. One blend means one batch record. That only helps if the COA shows each component.
          A single HPLC purity number for the whole powder does not. You need mass spectrometry peaks, or
          another method that can name each peptide.
        </p>
        <p className="leading-relaxed text-[#475569]">
          Dose-response work is the other failure mode. A four-peptide blend cannot give a clean EC50 for one
          ligand. The concentration of every component rises together. For titration curves, order the
          singles. Keep the blend for screens where the ratio is part of the design.
        </p>
        <p className="leading-relaxed text-[#475569]">
          The control set that usually works is the blend, each single component, and vehicle. Slow. Honest.
          It stops a lab from calling a vial synergistic when one peptide did almost all of the work.
        </p>

        <figure className="overflow-hidden rounded-xl">
          <Image
            src="/images/category/research-blends-1.jpg"
            alt="Research blends assay setup with BPC-157 TB-500 peptide blend vials, HPLC-MS overlay, and multi-well plate"
            width={1200}
            height={675}
            className="w-full object-cover"
            priority
          />
          <figcaption className="mt-2 text-center text-xs text-[#94A3B8]">
            Fixed-ratio peptide blend setup with HPLC-MS overlay and assay plate. Research use only.
          </figcaption>
        </figure>
      </section>

      <section id="blend-families" className="space-y-4">
        <h2 className="font-serif text-2xl text-[#0F172A]">Four peptide blend families</h2>
        <p className="leading-relaxed text-[#475569]">
          The research blends in this category fall into four groups: tissue repair, growth-hormone-axis
          signalling, incretin and amylin biology, and copper-peptide remodeling. Read them by pathway. Ignore
          the marketing nicknames until you have checked the label.
        </p>

        <h3 className="text-lg font-semibold text-[#0F172A]">Tissue-repair blends</h3>
        <p className="leading-relaxed text-[#475569]">
          The usual tissue-repair blend pairs{" "}
          <Link href="/bpc-157" className="text-[#0D9488] hover:underline">
            BPC-157
          </Link>{" "}
          with TB-500. Some SKUs add GHK-Cu or KPV. BPC-157 has angiogenesis work through VEGFR2-Akt-eNOS
          signalling in endothelial models.
          <a
            href="https://link.springer.com/article/10.1007/s00109-016-1488-y"
            target="_blank"
            rel="noopener noreferrer"
            className="text-[#0D9488] hover:underline"
          >
            {" "}
            [1]
          </a>
        </p>
        <p className="leading-relaxed text-[#475569]">
          TB-500 is harder. Vials sold under that name often contain a short thymosin beta-4 fragment, not
          the full protein used in many older papers. Our{" "}
          <Link href="/blog/bpc-157-vs-tb-500" className="text-[#0D9488] hover:underline">
            BPC-157 vs TB-500
          </Link>{" "}
          article walks through that gap. GHK-Cu brings copper-tripeptide remodeling biology. KPV is an
          alpha-MSH fragment used in inflammation models.
        </p>
        <p className="leading-relaxed text-[#475569]">
          So a product like{" "}
          <Link href="/glow-bpc-157-tb500-ghk-cu" className="text-[#0D9488] hover:underline">
            Glow Blend
          </Link>{" "}
          is three research questions in one vial: migration, angiogenesis, copper-peptide matrix effects. Use
          it when the protocol needs that combination. Use{" "}
          <Link href="/bpc-157" className="text-[#0D9488] hover:underline">
            BPC-157 alone
          </Link>{" "}
          when the question is BPC-157 alone.
        </p>

        <h3 className="text-lg font-semibold text-[#0F172A]">Growth-hormone-axis blends</h3>
        <p className="leading-relaxed text-[#475569]">
          GH-axis blends put a GHRH-side signal next to a ghrelin-receptor signal. CJC-1295 without DAC and
          sermorelin hit the GHRH receptor. Ipamorelin hits GHSR-1a. Different receptors. Same downstream GH
          conversation.
        </p>
        <p className="leading-relaxed text-[#475569]">
          A CJC-1295 study in healthy adults reported sustained GH and IGF-1 rises from the long-acting DAC
          form, with a half-life measured in days.
          <a
            href="https://doi.org/10.1210/jc.2005-1536"
            target="_blank"
            rel="noopener noreferrer"
            className="text-[#0D9488] hover:underline"
          >
            {" "}
            [2]
          </a>{" "}
          Ipamorelin was made as a selective GH secretagogue with less ACTH and cortisol activity than older
          GHRPs in early pharmacology work.
          <a
            href="https://pubmed.ncbi.nlm.nih.gov/9849822/"
            target="_blank"
            rel="noopener noreferrer"
            className="text-[#0D9488] hover:underline"
          >
            {" "}
            [3]
          </a>
        </p>
        <p className="leading-relaxed text-[#475569]">
          That is the point of{" "}
          <Link href="/cjc-1295-without-dac-ipamorelin-blend-10mg" className="text-[#0D9488] hover:underline">
            CJC-1295 without DAC plus ipamorelin
          </Link>
          : receptor convergence, not a vague claim of "more GH." Related singles and stacks sit in the{" "}
          <Link href="/category/growth-hormone-axis" className="text-[#0D9488] hover:underline">
            growth hormone axis
          </Link>{" "}
          category.
        </p>

        <h3 className="text-lg font-semibold text-[#0F172A]">Incretin and amylin blends</h3>
        <p className="leading-relaxed text-[#475569]">
          Cagrilintide plus semaglutide is the cleanest metabolic blend example with controlled combination
          data. Semaglutide is a GLP-1R agonist. Cagrilintide is a long-acting amylin analogue. Phase 2 and
          Phase 3 CagriSema trials report larger weight and glycaemic shifts for the combination than either
          monocomponent in several study designs.
          <a
            href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01163-7/abstract"
            target="_blank"
            rel="noopener noreferrer"
            className="text-[#0D9488] hover:underline"
          >
            {" "}
            [4]
          </a>{" "}
          <a
            href="https://europepmc.org/article/MED/42251859"
            target="_blank"
            rel="noopener noreferrer"
            className="text-[#0D9488] hover:underline"
          >
            [5]
          </a>
        </p>
        <p className="leading-relaxed text-[#475569]">
          The{" "}
          <Link href="/cagrilintide-semaglutide" className="text-[#0D9488] hover:underline">
            cagrilintide semaglutide blend
          </Link>{" "}
          here is an RUO fixed-ratio reagent. Run it against semaglutide alone, cagrilintide alone, and
          vehicle. More incretin context is on the{" "}
          <Link href="/category/glp-1-research" className="text-[#0D9488] hover:underline">
            GLP-1 research
          </Link>{" "}
          page.
        </p>

        <figure className="overflow-hidden rounded-xl">
          <Image
            src="/images/category/research-blends-2.jpg"
            alt="Illustrated peptide blends pathway model showing angiogenesis, cell migration, matrix remodeling, and inflammation control"
            width={1200}
            height={675}
            className="w-full object-cover"
          />
          <figcaption className="mt-2 text-center text-xs text-[#94A3B8]">
            A blend fits studies that already need multiple pathway readouts.
          </figcaption>
        </figure>
      </section>

      <section id="naming-traps" className="space-y-4">
        <h2 className="font-serif text-2xl text-[#0F172A]">Nicknames vs. catalog identity</h2>
        <p className="leading-relaxed text-[#475569]">
          Glow, KLOW, Wolverine, and similar names show up in search. They are seller shorthand. They are
          not INNs. Two vendors can use the same nickname for different milligram splits.
        </p>
        <p className="leading-relaxed text-[#475569]">
          Write the materials section with the catalog identity: each peptide name, each mass in the vial,
          and the lot number. If a paper cites "Glow Blend" without a ratio, you cannot match it. If your
          own notebook only says "Wolverine," nobody can reproduce the work.
        </p>
        <p className="leading-relaxed text-[#475569]">
          Analytical load scales with component count. Two peptides mean two identity checks. Four peptides
          mean four. A COA that lists one purity percentage for an 80 mg four-peptide vial is incomplete.
          Ask for peaks or content data that map to each sequence.
        </p>
        <p className="leading-relaxed text-[#475569]">
          Ratio on the label and ratio on the COA should match. If the vial says 10 mg BPC-157 and 10 mg
          TB-500, the analytical record should say the same. A mismatch is a reason to quarantine the lot,
          not a rounding error to ignore.
        </p>
      </section>

      <section id="best-blend" className="space-y-4">
        <h2 className="font-serif text-2xl text-[#0F172A]">How to choose the best peptide blend for a study</h2>
        <p className="leading-relaxed text-[#475569]">
          The best peptide blends look dull on a spreadsheet. Clear endpoint. Short component list.
          Acceptance rules written before day one.
        </p>
        <ol className="list-decimal space-y-2 pl-5 text-[#475569]">
          <li className="leading-relaxed">
            Does each component map to the endpoint, or is one there because the nickname sells?
          </li>
          <li className="leading-relaxed">
            Can you run each component alone in parallel? If not, attribution will stay soft.
          </li>
          <li className="leading-relaxed">
            Does the fixed ratio fit the model, or would singles give better concentration control?
          </li>
          <li className="leading-relaxed">
            Does the COA verify each component by identity, or does it stop at a total purity number?
          </li>
          <li className="leading-relaxed">
            Does lower prep variation matter more than losing independent titration?
          </li>
        </ol>
        <p className="leading-relaxed text-[#475569]">
          A rough score we use internally: endpoint fit 2 points, component-level COA 2, single-component
          control feasibility 2, ratio fit 1, handling simplicity 1. Under six points, split the work into
          singles. That is not a universal assay law. It catches most weak blend choices before the first
          plate is poured.
        </p>
      </section>

      <section id="evidence-problem" className="space-y-4">
        <h2 className="font-serif text-2xl text-[#0F172A]">Why blend evidence is harder</h2>
        <p className="leading-relaxed text-[#475569]">
          Evidence for a blend is not the same as evidence for every ingredient. BPC-157 has angiogenesis
          data. GHK-Cu has skin and matrix papers. Cagrilintide plus semaglutide has controlled combination
          trials. Those are different evidence types. They do not travel across categories for free.
        </p>
        <p className="leading-relaxed text-[#475569]">
          Attribution is the hard part. A three-peptide blend improves a readout. Was it additive? One
          dominant compound? An interaction? An artifact of the fixed ratio? One blend arm cannot answer.
          You need singles, the blend, and vehicle.
        </p>
        <p className="leading-relaxed text-[#475569]">
          This is where many peptide blends for sale pages fail. They cite one strong paper for one
          component, then write as if the whole vial proved the same endpoint. Keep the claim attached to
          the molecule and model that produced it.
        </p>
      </section>

      <section id="storage" className="space-y-4">
        <h2 className="font-serif text-2xl text-[#0F172A]">Storage and prep notes for multi-peptide vials</h2>
        <p className="leading-relaxed text-[#475569]">
          Keep lyophilized research blends at -20°C, dry, and dark until you open them. After reconstitution
          under your lab SOP, aliquot. Avoid repeated freeze-thaw. Document solvent, concentration, and hold
          time on every tube.
        </p>
        <p className="leading-relaxed text-[#475569]">
          Multi-peptide powder is messier than a single sequence. Components can adsorb to plastic at
          different rates. Copper-containing peptides such as GHK-Cu add another handling variable. Glass or
          low-bind plastic and a written stock protocol cut most of that noise.
        </p>
        <p className="leading-relaxed text-[#475569]">
          When you convert mass to molar stock for in-vitro work, look up each component molecular weight
          separately (PubChem is fine for that). A blend label in milligrams is not a molarity. Cold-chain
          shipping details are on the{" "}
          <Link href="/shipping" className="text-[#0D9488] hover:underline">
            shipping
          </Link>{" "}
          page. Diluents and related reagents sit under{" "}
          <Link href="/category/lab-supplies" className="text-[#0D9488] hover:underline">
            lab supplies
          </Link>
          .
        </p>
        <p className="leading-relaxed text-[#475569]">
          Fatty-acylated components such as semaglutide stick to untreated polypropylene more than short
          linear peptides. In a cagrilintide plus semaglutide blend, that can skew free concentrations after
          the stock sits in the wrong tube. Measure or aliquot quickly. Do not assume every peptide in the
          mix behaves the same on plastic.
        </p>
      </section>

      <section id="buying-checks" className="space-y-4">
        <h2 className="font-serif text-2xl text-[#0F172A]">Checks before buying peptide blends for sale</h2>
        <p className="leading-relaxed text-[#475569]">
          Before you buy peptide blends for sale as RUO reagents, open the{" "}
          <Link href="/coa-library" className="text-[#0D9488] hover:underline">
            COA Library
          </Link>
          . Look for component identity, lot linkage, and storage state. The lot on the vial should match the
          lot on the COA. The method should be able to tell peptides apart. Purity or content data should not
          hide one component behind a single total.
        </p>
        <p className="leading-relaxed text-[#475569]">
          Prefer lyophilized powder over pre-dissolved liquid for shelf life. Confirm{" "}
          <Link href="/shipping" className="text-[#0D9488] hover:underline">
            cold-chain shipping
          </Link>
          . Keep the order under{" "}
          <Link href="/ruo" className="text-[#0D9488] hover:underline">
            research use only
          </Link>{" "}
          rules.
        </p>
        <p className="leading-relaxed text-[#475569]">
          The product grid above lists current research blends and strengths. For tissue-repair comparators,
          use{" "}
          <Link href="/category/tissue-repair" className="text-[#0D9488] hover:underline">
            tissue repair
          </Link>
          . For endocrine-axis controls, use the GH-axis category. For incretin controls, use GLP-1 research.
          Blends answer a combined question. Singles answer attribution.
        </p>

        <figure className="overflow-hidden rounded-xl">
          <Image
            src="/images/category/research-blends-3.jpg"
            alt="Lot-linked COA and mass spectrometry verification for research peptide blends before laboratory purchase"
            width={1200}
            height={675}
            className="w-full object-cover"
          />
          <figcaption className="mt-2 text-center text-xs text-[#94A3B8]">
            Component identity and lot linkage beat a generic purity claim.
          </figcaption>
        </figure>
      </section>

      <section className="space-y-4 rounded-xl border border-[#E2E8F0] bg-[#F8FAFC] p-6">
        <h2 className="font-serif text-xl text-[#0F172A]">
          Conclusion: use a research blend when the design needs a fixed ratio
        </h2>
        <p className="leading-relaxed text-[#475569]">
          Research blends work when the study is already multi-pathway and a locked ratio makes the work
          cleaner. They fail when they replace controls. Name the endpoint. Name each component. Check the
          lot. Keep singles nearby if you care about attribution.
        </p>
        <p className="leading-relaxed text-[#475569]">
          Tetrava sells peptide blends for laboratory research only. Read the specs, open the COA, pick the
          reagent that fits the model. Not the longest label.
        </p>
        <div className="flex flex-wrap gap-3">
          <Link href="/shop" className="btn-primary text-sm">
            Browse peptide blends
          </Link>
          <Link href="/coa-library" className="btn-secondary text-sm">
            View COA library
          </Link>
        </div>
      </section>

      <section className="space-y-2 border-t border-[#E2E8F0] pt-6 text-xs text-[#94A3B8]">
        <p className="font-medium text-[#475569]">References</p>
        <ol className="list-decimal space-y-1 pl-5">
          <li>
            BPC-157 and VEGFR2-Akt-eNOS angiogenesis signalling.{" "}
            <a
              href="https://link.springer.com/article/10.1007/s00109-016-1488-y"
              target="_blank"
              rel="noopener noreferrer"
              className="text-[#0D9488] hover:underline"
            >
              Journal of Molecular Medicine
            </a>
          </li>
          <li>
            CJC-1295 GH and IGF-1 pharmacology.{" "}
            <a
              href="https://doi.org/10.1210/jc.2005-1536"
              target="_blank"
              rel="noopener noreferrer"
              className="text-[#0D9488] hover:underline"
            >
              Journal of Clinical Endocrinology and Metabolism
            </a>
          </li>
          <li>
            Ipamorelin GH secretagogue selectivity.{" "}
            <a
              href="https://pubmed.ncbi.nlm.nih.gov/9849822/"
              target="_blank"
              rel="noopener noreferrer"
              className="text-[#0D9488] hover:underline"
            >
              PubMed 9849822
            </a>
          </li>
          <li>
            Cagrilintide plus semaglutide Phase 2 study.{" "}
            <a
              href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01163-7/abstract"
              target="_blank"
              rel="noopener noreferrer"
              className="text-[#0D9488] hover:underline"
            >
              The Lancet
            </a>
          </li>
          <li>
            REIMAGINE 2 cagrilintide-semaglutide Phase 3 study.{" "}
            <a
              href="https://europepmc.org/article/MED/42251859"
              target="_blank"
              rel="noopener noreferrer"
              className="text-[#0D9488] hover:underline"
            >
              Europe PMC
            </a>
          </li>
        </ol>
      </section>
    </article>
  )
}
